L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes

Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes. While many of these immune evasion networks include checkpoint proteins, small molecular weight compounds, such as the amino acid L-kynurenine (LKU), could also substantially contrib...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephanie Schlichtner, Inna M. Yasinska, Elena Klenova, Maryam Abooali, Gurprit S. Lall, Steffen M. Berger, Sabrina Ruggiero, Dietmar Cholewa, Milan Milošević, Bernhard F. Gibbs, Elizaveta Fasler-Kan, Vadim V. Sumbayev
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2244330
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850059940850302976
author Stephanie Schlichtner
Inna M. Yasinska
Elena Klenova
Maryam Abooali
Gurprit S. Lall
Steffen M. Berger
Sabrina Ruggiero
Dietmar Cholewa
Milan Milošević
Bernhard F. Gibbs
Elizaveta Fasler-Kan
Vadim V. Sumbayev
author_facet Stephanie Schlichtner
Inna M. Yasinska
Elena Klenova
Maryam Abooali
Gurprit S. Lall
Steffen M. Berger
Sabrina Ruggiero
Dietmar Cholewa
Milan Milošević
Bernhard F. Gibbs
Elizaveta Fasler-Kan
Vadim V. Sumbayev
author_sort Stephanie Schlichtner
collection DOAJ
description Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes. While many of these immune evasion networks include checkpoint proteins, small molecular weight compounds, such as the amino acid L-kynurenine (LKU), could also substantially contribute to the suppression of anti-cancer immunity. However, the biochemical mechanisms underlying the suppressive effects of LKU on T-cells remain unclear. Here, we report for the first time that LKU suppresses T cell function as an aryl hydrocarbon receptor (AhR) ligand. The presence of LKU in T cells is associated with AhR activation, which results in competition between AhR and hypoxia-inducible factor 1 alpha (HIF-1α) for the AhR nuclear translocator, ARNT, leading to T cell exhaustion. The expression of indoleamine 2,3-dioxygenase 1 (IDO1, the enzyme that leads to LKU generation) is induced by the TGF-β-Smad-3 pathway. We also show that IDO-negative cancers utilize an alternative route for LKU production via the endogenous inflammatory mediator, the high mobility group box 1 (HMGB-1)-interferon-gamma (IFN-γ) axis. In addition, other IDO-negative tumors (like T-cell lymphomas) trigger IDO1 activation in eosinophils present in the tumor microenvironment (TME). These mechanisms suppress cytotoxic T cell function, and thus support the tumor immune evasion machinery.
format Article
id doaj-art-af8e958bbeec46739a4b45819fd24cbb
institution DOAJ
issn 2162-402X
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series OncoImmunology
spelling doaj-art-af8e958bbeec46739a4b45819fd24cbb2025-08-20T02:50:44ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2244330L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytesStephanie Schlichtner0Inna M. Yasinska1Elena Klenova2Maryam Abooali3Gurprit S. Lall4Steffen M. Berger5Sabrina Ruggiero6Dietmar Cholewa7Milan Milošević8Bernhard F. Gibbs9Elizaveta Fasler-Kan10Vadim V. Sumbayev11Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKSchool of Biological Sciences, University of Essex, Colchester, UKMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKDepartment of Pediatric Surgery, Children’s Hospital, Inselspital Bern, University of Bern and Department of Biomedical Research, University of Bern, Bern, SwitzerlandDepartment of Pediatric Surgery, Children’s Hospital, Inselspital Bern, University of Bern and Department of Biomedical Research, University of Bern, Bern, SwitzerlandDepartment of Pediatric Surgery, Children’s Hospital, Inselspital Bern, University of Bern and Department of Biomedical Research, University of Bern, Bern, SwitzerlandDepartment of Pediatric Surgery, Children’s Hospital, Inselspital Bern, University of Bern and Department of Biomedical Research, University of Bern, Bern, SwitzerlandMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKDepartment of Pediatric Surgery, Children’s Hospital, Inselspital Bern, University of Bern and Department of Biomedical Research, University of Bern, Bern, SwitzerlandMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UKMalignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes. While many of these immune evasion networks include checkpoint proteins, small molecular weight compounds, such as the amino acid L-kynurenine (LKU), could also substantially contribute to the suppression of anti-cancer immunity. However, the biochemical mechanisms underlying the suppressive effects of LKU on T-cells remain unclear. Here, we report for the first time that LKU suppresses T cell function as an aryl hydrocarbon receptor (AhR) ligand. The presence of LKU in T cells is associated with AhR activation, which results in competition between AhR and hypoxia-inducible factor 1 alpha (HIF-1α) for the AhR nuclear translocator, ARNT, leading to T cell exhaustion. The expression of indoleamine 2,3-dioxygenase 1 (IDO1, the enzyme that leads to LKU generation) is induced by the TGF-β-Smad-3 pathway. We also show that IDO-negative cancers utilize an alternative route for LKU production via the endogenous inflammatory mediator, the high mobility group box 1 (HMGB-1)-interferon-gamma (IFN-γ) axis. In addition, other IDO-negative tumors (like T-cell lymphomas) trigger IDO1 activation in eosinophils present in the tumor microenvironment (TME). These mechanisms suppress cytotoxic T cell function, and thus support the tumor immune evasion machinery.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2244330cancerimmune checkpointsimmune escapekynurenineT cells
spellingShingle Stephanie Schlichtner
Inna M. Yasinska
Elena Klenova
Maryam Abooali
Gurprit S. Lall
Steffen M. Berger
Sabrina Ruggiero
Dietmar Cholewa
Milan Milošević
Bernhard F. Gibbs
Elizaveta Fasler-Kan
Vadim V. Sumbayev
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
OncoImmunology
cancer
immune checkpoints
immune escape
kynurenine
T cells
title L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
title_full L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
title_fullStr L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
title_full_unstemmed L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
title_short L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes
title_sort l kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in t lymphocytes
topic cancer
immune checkpoints
immune escape
kynurenine
T cells
url https://www.tandfonline.com/doi/10.1080/2162402X.2023.2244330
work_keys_str_mv AT stephanieschlichtner lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT innamyasinska lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT elenaklenova lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT maryamabooali lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT gurpritslall lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT steffenmberger lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT sabrinaruggiero lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT dietmarcholewa lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT milanmilosevic lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT bernhardfgibbs lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT elizavetafaslerkan lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes
AT vadimvsumbayev lkynurenineparticipatesincancerimmuneevasionbydownregulatinghypoxicsignalingintlymphocytes